Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5156789 | 0.78 | — | — | |
| SCHEMBL21293786 | 0.78 | — | — | |
| SCHEMBL447191 | 0.78 | — | — | |
| SCHEMBL7152186 | 0.78 | — | — | |
| SCHEMBL4502028 | 0.78 | TDP1 (0.33) | TDP1 | |
| SCHEMBL9563418 | 0.78 | — | — | |
| SCHEMBL6209232 | 0.77 | ADH1C (0.36) | — | |
| SCHEMBL3982585 | 0.75 | — | — | |
| SCHEMBL6006558 | 0.75 | TDP1 (0.31) | TDP1 | |
| SCHEMBL6640905 | 0.75 | HIF1A (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057944-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2025-02-20 | — | — | US | disclosed |
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20250002522-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2025-01-02 | — | — | US | disclosed |
| US-20240425541-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2024-12-26 | — | — | US | disclosed |
| US-20240417418-A1 | DISULFIDE OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2024-12-19 | — | — | US | disclosed |
| EP-4401788-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| EP-4402149-A1 | DISULFIDE OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| EP-4286004-A1 | DISULFIDE OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2023-12-06 | — | — | EP | disclosed |
| EP-4286003-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2023-12-06 | — | — | EP | disclosed |
| EP-4286394-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2023-12-06 | — | — | EP | disclosed |
| US-6087355-A | A THERAPEUTIC BACTERICIDE COMPOSITION FOR TREATING A METHICILLIN-RESISTANT, VANCOMYCIN-RESISTANT, OR AMPICILLIN-RESISTANT BACTERIAL INFECTION | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-07-11 | — | — | US | disclosed |
| US-6066630-A | ACTIVE AGAINST ANTIBIOTIC RESISTANT BACTERIA | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-05-23 | — | — | US | disclosed |
| US-6057312-A | TREATING ANTIBIOTIC RESISTANT BACTERIAL INFECTIONS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-05-02 | — | — | US | disclosed |
| US-6030965-A | WIDE SPECTRAM ANTIBIOTICS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-02-29 | — | — | US | disclosed |
| US-6025352-A | Cephalosporin antibiotics | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-6005116-A | HAVE INHIBITION ACTIVITIES AGAINST TYPE A-MONOAMINE OXIDASE; TREATING OR PREVENTING DEPRESSION, PARKINSON'S DISEASE, ALZEHEIMER'S DEMENTIA, OR CEREBROVASCULAR DEMENTIA | SANKYO COMPANY, LIMITED (JP) | 1999-12-21 | — | — | US | disclosed |
| US-5859256-A | CHLORINATION; USEFUL AS ANTIBACTERIAL AGENTS AND IN TREATING DISEASES CAUSED BY ORGANISMS WHICH ARE RESISTANT TO BETA-LACTAM ANTIBIOTICS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0885891-A1 | ISOXAZOLE DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
| EP-0874854-A2 | CEPHALOSPORIN ANTIBIOTICS | Microcide Pharmaceuticals, Inc. (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997013772-A2 | CEPHALOSPORIN ANTIBIOTICS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1997-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057944-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | FUT6, NSUN3, OSTC | TDP1 2485/4885 |
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | CD4, FUT6, UGCG | TDP1 4398/4885 |
| US-20250002522-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | OSTC, FUT6, MAN2B2 | TDP1 1306/4885 |
| US-20240425541-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | OSTC, SNRPA, RNASE1 | TDP1 1188/4885 |
| US-20240417418-A1 | DISULFIDE OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | DNAJC10, SNRPA, SNRPA1 | TDP1 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.